《新股消息》微創醫療(00853.HK)旗下微創機器人傳來港上市 籌最多10億美元
據路透旗下IFR引述消息指,微創醫療(00853.HK)旗下微創醫療機器人股份正計劃年內來港上市,集資約7億至10億美元,正與中金公司和摩根大通合作,籌備上市相關工作。
另外有消息指,微創機器人最快本月正式提交上市申請。
資料顯示,公司主要專注於機器人智能手術全解方案的研究和產業集成。據中金公司早前公布的上海微創醫療機器人上市輔導備案報告,微創醫療持股53.75%,高瓴資本持股約7.99%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.